The balance sheet gives him room to move - Lal PathLabs is sitting on about Rs.1,400 crore of net cash and no debt, and can ...

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions ...

Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) is set to release its Q2 2026 earnings on Oct 31, 2025. The consensus estimate for Q2 2026 revenue is $7.38 billion, and the earnings are expected to come in at ...

Dr Lal PathLabs on Friday, January 30, reported a mixed set of numbers for the December quarter. Net profit fell 6.4% year-on ...

Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes ...

This article first appeared on GuruFocus. Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) is set to release its Q3 2026 earnings on Jan 30, 2026. The consensus estimate for Q3 2026 revenue is $6.66 billion, and ...

Dr Lal PathLabs Q3 results date: Diagnostics company Dr Lal PathLabs is slated to meet next to consider and approve its financial results for the quarter ended December 30, 2024 (Q3), the company ...

Healthcare service provider Dr Lal Pathlabs announced, on Thursday, that board will meet on July 31 to announce the financial results for the quarter ending on June 30, 2025. The healthcare stock has ...

The record date for the interim dividend will be August 06, 2025. The company will pay the dividend within 30 days of its declaration. The company will pay a Rs 6 per share dividend. Image: Freepik | ...

NEW DELHI: Diagnostic services provider Dr Lal PathLabs is making headlines after a leaked medical report alleged that Olympic gold medalist boxer Imane Khelif has male chromosomes. The test, ...